| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Anaesthesia and General Intensive Care Medicine, University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.
Address correspondence to: Univ. Prof. Dr. Friedrich K. Pühringer. Phone: 43-512-504-4319; Fax: 43-512-504-2450; E-mail: friedrich.puehringer{at}uibk.ac.at
Purpose: Controversial data about the effect of smoking on the dose-requirements and the pharamcodynamics of rocuronium have been reported recently. This study was conducted to evaluate the dose-requirements and the pharmacodynamics of rocuronium in smokers using target controlled infusion.
Methods: The dose-requirements of rocuronium for 60 min relaxation, using target controlled infusion, given under intravenous anaesthesia with propofol, fentanyl and nitrous oxide was studied in 37 smokers and 37 non-smokers. Initially 450 µgkg1 rocuronium were administered, neuromuscular effects were quantified by recording the single twitch response of the adductor pollicis muscle after ulnar nerve stimulation using a force transducer, and the neuromuscular block was kept at 80% by target controlled infusion throughout the procedure.
Results: The dose-requirements for one hour relaxation were 867 ± 116 µgkg1hr1 for smokers (S) and 839 ± 149 µgkg1hr1 for non-smokers (NS). The duration to 10% and the spontaneous recovery from 25% to 75% of the control twitch response also showed no differences between S (17.2 ± 3.4 min, 10.6 ± 0.9 min ) and NS (18.9 ± 4.3 min, 10.9 ± 3.2 min), as well as maximum block, onset time and infusion rate.
Conclusion: Smoking does not alter the dose-requirements for rocuronium and no effects on the onset time, degree of block, time to maximum block, duration 10% and spontaneous recovery index were observed.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |